STAT+: Pharmalittle: We’re reading about FDA hiring delays, a new Bavarian Nordic CEO, and more
For all the talk of a hiring spree at the FDA after DOGE cuts last year, the reality is more complicated and filled with bureaucratic delays
Today's headlines include a multi-faceted story revolving around the U.S. Food and Drug Administration (FDA), the new CEO of Bavarian Nordic, and the complexities surrounding FDA hiring delays. The FDA's hiring process has been marred by bureaucratic delays, primarily due to DOGE cuts that wiped out thousands of jobs during the Trump administration. As a result, prospective new employees are currently stuck in a state of pre-onboarding limbo, while other routine administrative tasks have been neglected.
One aspect of the FDA story involves the challenges faced by potential hires amidst the bureaucratic delays. These delays have caused a backlog of routine administrative tasks, such as purchase approvals and travel payments. This situation highlights the inefficiency and confusion that has arisen from the DOGE cuts, which have had far-reaching consequences on the hiring process at the FDA.
In other news, Bavarian Nordic has appointed former Sanofi executive Tarja Stenvall as its new chief executive officer. The appointment comes in the wake of a failed takeover bid, which led to the resignation of the previous chairman and CEO. Stenvall will assume her new role on October 15, replacing Paul Chaplin. Bavarian Nordic is a Danish company best known for its smallpox vaccine, which is also used against mpox.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
